GU Cancers Symposium 2014 - The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery...

SAN FRANCISCO, CA USA (UroToday.com) - Complete Title: GU Cancers Symposium 2014 - The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer - Session Highlights

Dr. M. Dror Michaelson and colleagues reported on the RTOG 0524 trial, looking at the safety and efficacy of trimodality, organ-preserving therapy in patients with UC overexpress HER2/neu, who were not suitable for radical cystectomy. Patients with invasive bladder UC (stages T2-T4a, N0-1, M0) who underwent cystoscopic tumor resection were analyzed by HER2/neu immunohistochemistry (IHC) and assigned to chemotherapy groups I (IHC 2+ or 3+; paclitaxel and trastuzumab) or II (IHC negative or 1+; paclitaxel alone). Concurrent weekly paclitaxel (50 mg/m2), weekly trastuzumab (group I only) and daily radiation (64.8 Gy total in 36 fractions) were also given for seven consecutive weeks. The primary endpoint of the study was acute protocol-defined toxicity related to treatment.

gucancerssympalt thumbTwenty-one eligible patients were included in group I and 47 in group 2. Median ages were 80 and 73, respectively. Acute toxicity was observed in 7/21 patients (33%) in group I and 14/47 patients (30%) in group II. Most common grade > 3 adverse events in groups I and II were marrow suppression (43% and 17%), diarrhea (33% and 30%), and hyponatremia (14% and 4%). Three deaths on study were attributed to colonic perforation, pneumonia, and sudden death. Radiation completion rates were 72% and 85% in the two groups, and full-dose chemotherapy completion rates were 52% and 51%. Evaluation by cystoscopy and/or tumor biopsy at 12 weeks noted complete response in 9/13 patients (69%) in group I, in 19/33 patients (58%) in group II, and was not performed in the remaining patients.

They concluded that although the response rate for HER2/neu-targeted therapy is acceptable, it may also increase certain adverse events in this challenging population. Also, they show that trimodality bladder-preserving therapy can be an appropriate treatment in patient with invasive UC who do not have adequate cardiopulmonary reserve to undergo radical cystectomy.

Highlights of a presentation by M. Dror Michaelson, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Massachusetts General Hospital, Boston, MA USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland